Chronic myeloid leukemia patients taking standard dasatinib maintain strong disease control when skipping treatment on weekends, according to trial findings published on November 13, 2026.
Researchers evaluated standard daily treatment against a five-day-on, two-day-off schedule in the German Chronic Myeloid Leukemia Alliance randomized trial published in the Journal of Clinical Oncology. Out of 260 patients evaluated, 206 achieved major molecular remission at 24 months, representing 79% of the cohort.
Continuous dosing produced an 81% remission rate, while the intermittent weekend break schedule achieved 78%. While continuous treatment showed a three-percentage-point advantage, the intermittent approach met the prespecified noninferiority criterion with a 15% margin.
For second-line or later treatment patients, continuous dosing reached 87% compared to 62.5% for intermittent dosing, meaning noninferiority was not established in that group. Investigators said that those subgroup analyses were not prespecified and should be considered exploratory.
In the standard arm, 105 of 130 patients achieved major molecular remission at 24 months, representing 81% with a 95% confidence interval from 74% to 88%.
A post hoc analysis of toxicities of special interest, specifically pleural and pericardial effusion, showed that 21 of 130 patients, or 16%, experienced these events in the standard arm.
Conversely, the analysis showed that 10 of 125 patients, or 8%, in the experimental arm encountered the same fluid-related toxicities, yielding a statistically significant p-value of .0464.
Grade 2 to 4 adverse events occurred in 58% of patients on continuous treatment and 56% on intermittent dosing, with median cumulative toxicity scores matching at two in both arms. However, an exploratory post hoc analysis revealed differences in pleural and pericardial effusions.
These specific effusions affected 16% of patients receiving continuous dosing, compared to 8% of those on the intermittent schedule. A separate post hoc time-to-event analysis recorded 24-month cumulative incidence rates of 16% and 7% respectively.
Investigators emphasized that treatment tolerability and health-related quality of life remain important considerations as patients achieve long-term disease control with tyrosine kinase inhibitors. They said that distinguishing intolerance from disease resistance is vital when evaluating modifications like dose adjustments.
Intermittent dasatinib dosing achieved “noninferior molecular efficacy with favorable effects on HRQOL and selected toxicities,” said Paul La Rosée and co-investigators.